In 2017 we will be launching MCG-International (MCG-I).

Many centres around the world are now adopting the principles, processes, tests and/or tools that the MCG have developed.

MCG-I is an international collaborative project to share experiences and good practice in cancer predisposition gene testing.

A primary objective of MCG-I is to facilitate mainstream testing for the BRCA1 and BRCA2 genes for ovarian cancer patients across the world.